U.S. Food and Drug Administration Approves BioMarin's VOXZOGO® (vosoritide) for Children Under 5 Years with Achondroplasia

/PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, today...

Related Keywords

Brazil ,Australia ,Japan ,Andrew Villani ,Traci Mccarty ,Biomarin Rareconnections ,Hank Fuchs ,William Wilcox ,Committee For Medicinal Products Human Use ,Biomarin Pharmaceutical Inc ,European Commission ,Emory University ,Worldwide Research ,European Medicines Agency ,Drug Administration ,Exchange Commission ,Nasdaq ,Expanded Indication ,Includes Children ,Biomarin Pharmaceutical ,New Drug Application ,Paediatric Endocrinology Meeting ,Medicinal Products ,Human Use ,Drug Designation ,Case Manager ,Biomarin Medical Information ,Prescribing Information ,Quarterly Report ,Marin Pharmaceutical ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Biotechnology ,Pharmaceuticals ,Fda Approval ,